Predictive Factors in Response to Inhaled Corticoids in Chronic Cough (FeNOTX)

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Status: Unknown

Conditions: Healthy

Treatments: Drug: Placebo; Drug: Budesonide novolizer

Study type: Interventional

Funder types: Other

Identifiers

NCT02715167

FeNOTX

Details and patient eligibility

About

The hypothesis is that a high fractional exhaled nitric oxide can predict the response to inhaled corticoids in chronic cough.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• chronic cough

Exclusion criteria

• active smoker
• treated by corticoids during the previous month
• use of angiotensin-converting-enzyme inhibitor

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

100 participants in 2 patient groups, including a placebo group

Group Budesonide

Active Comparator group

Description:

Inhaled corticoids

Treatment:

Drug: Budesonide novolizer

Group Placebo

Placebo Comparator group

Description:

Placebo by inhalation

Treatment:

Drug: Placebo